Medinotec INC

Medinotec, Inc. announced the results of its 2025 Annual Meeting, where shareholders re-elected all directors and ratified Mercurius & Associates LLP as the independent auditor for fiscal 2026.

Medinotec Inc. has scheduled its 2024 annual meeting of stockholders to be held virtually on February 19, 2025, with key proposals including the election of directors and the approval of the company's independent auditor.

Medinotec Inc. has dismissed BDO South Africa Inc. and engaged Mercurius & Associates LLP as its new independent registered public accounting firm, citing previously identified material weaknesses in internal controls.

Medinotec's 2023 Annual Meeting saw the election of all director nominees but the rejection of the proposed independent auditor ratification.

Medinotec Inc. has scheduled its 2023 annual shareholder meeting for March 19, 2024, to be held virtually, with key proposals including the election of directors and the approval of the company's independent auditor.

Medinotec Inc. announced its first-quarter fiscal year 2026 results, showcasing a 24% increase in revenue and a significant rise in net income driven by improved gross margins and a tax benefit.

Medinotec Inc. reported significant profit growth and substantial debt reduction in its Q3 2025 filing, driven by international sales, despite U.S. revenue decline and tariff concerns.

Medinotec Inc. reported significant revenue growth in Q2 2026, driven by international distribution, but faces challenges from a new U.S. tariff, customer concentration, and ineffective disclosure controls.

Medinotec, Inc. announced a significant 70.5% revenue increase for the quarter ended May 31, 2025, driven by international distribution, but faced gross margin contraction, negative operating cash flow, and a new 30% U.S. tariff on South African imports.

Medinotec Inc. saw a significant increase in revenue for the quarter ended November 30, 2024, primarily driven by its international sales segment and the expansion of its distribution network.

Medinotec Inc. reports a significant increase in revenue for the quarter ended August 31, 2024, primarily driven by international sales and the expansion of its distribution network.

Medinotec reports fiscal 2026 revenue of $9.7 million, driven by international distribution growth despite U.S. market challenges.

Medinotec, Inc. announced a significant financial turnaround in its fiscal year ended February 28, 2025, reporting an 81.5% surge in revenue and a shift from a net loss to a substantial net income, primarily fueled by new distribution agreements in South Africa and successful commercialization of its Trachealator device in the United States.

Medinotec Inc. experienced a significant revenue increase in fiscal year 2024, driven by new distribution agreements and sales of its Trachealator product in the United States.

Medinotec, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on January 20, 2026, to elect five directors and approve its independent auditor.

Stavros G. Vizirgianakis, a board member of Medinotec Inc., has filed a Schedule 13D disclosing beneficial ownership of 4,750,179 shares, representing 40.4% of the company's common stock.

Gregory Vizirgianakis, a board member of Medinotec Inc., has filed a Schedule 13D disclosing beneficial ownership of 4,750,179 shares, representing 40.4% of the company's common stock.